Silica-based mesoporous nanoparticles for controlled drug delivery

Journal of Tissue Engineering

Volumn 4, Issue 1, 2013, Pages 1-18

  Kwon, Sooyeon ^a   Singh, Rajendra K ^b,c   Perez, Roman A ^c   Neel, Ensanya A Abou ^d,e,f   Kim, Hae Won ^b,c,g   Chrzanowski, Wojciech ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BK21 Plus NBM Global Research Center for Regenerative Medicine   (South Korea)

^c Dankook University   (South Korea)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e TANTA UNIVERSITY   (Egypt)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g Dankook University   (South Korea)

Author keywords

Chemotherapy; Controlled release; Mesoporous silica nanoparticle; Sol gel process; Targeted drug delivery

Indexed keywords

BIOCOMPATIBILITY; CHEMICAL STABILITY; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; MESOPOROUS MATERIALS; MOLECULES; PORE SIZE; SILICA NANOPARTICLES; SOL-GEL PROCESS; SURFACE PROPERTIES;

ADVERSE DRUG REACTIONS; CONTROLLED RELEASE; DRUG CARRIER; DRUG MOLECULES; HIGH DOSE; MESOPOROUS NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLES; PROPERTY; TARGET SITES; THERAPEUTIC EFFECTS;

TARGETED DRUG DELIVERY;

ALENDRONIC ACID; AMOXICILLIN; CAMPTOTHECIN; CARBON NANOTUBE; DENDRIMER; DOXORUBICIN; DRUG CARRIER; ERYTHROMYCIN; GOLD NANOPARTICLE; IBUPROFEN; LIPOSOME; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; NAPROXEN; SILANE; SILICIC ACID; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRAMETHOXYSILANE; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

BIOSAFETY; CONTROLLED DRUG RELEASE; HUMAN; IRRADIATION; NONHUMAN; PH; REVIEW; TEMPERATURE;

EID: 84888638494     PISSN: None     EISSN: 20417314     Source Type: Journal    
DOI: 10.1177/2041731413503357     Document Type: Review

References (134)

1. Jyrkka J, Mursu J, Enlund H, et al. Polypharmacy and nutritional status in elderly people. Curr Opin Clin Nutr 2012; 15(1): 1-6.
2. Zhang M, Holman CDJ, Preen DB, et al. Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980-2003. Brit J Clin Pharmaco 2007; 63(2): 163-170.
3. Ferner RE. Medication errors. Brit J Clin Pharmaco 2012; 73(6): 912-916.
4. McLean AJ and Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56(2): 163-184.
5. Plank C, Anton M, Rudolph C, et al. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Th 2003; 3(5): 745-758.
6. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Ch 2008; 52(4): 1330-1336.
7. Lu J, Liong M, Zink JI, et al. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007; 3(8): 1341-1346.
8. Liu YJ, Zhang B and Yan B. Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel. Int J Mol Sci 2011; 12(7): 4395-4413.
9. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21(23): 2475-2490.
10. Kim YJ, Choi S, Koh JJ, et al. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharmaceut Res 2001; 18(4): 548-550.
11. Arshady R. Preparation of biodegradable microspheres and microcapsules: 2. Polyactides and related polyesters. J Control Release 1991; 17(1): 1-21.
12. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm 1995; 116(1): 1-9.
13. Panyam J and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliver Rev 2003; 55(3): 329-347.
14. Sanders LM, Kell BA, McRae GI, et al. Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer. J Pharm Sci 1986; 75(4): 356-360.
15. Kailasam S, Wise DL and Gangadharam PRJ. Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer. J Antimicrob Chemoth 1994; 33(2): 273-279.
16. Li LC, Deng J and Stephens D. Polyanhydride implant for antibiotic delivery - from the bench to the clinic. Adv Drug Deliver Rev 2002; 54(7): 963-986.
17. Saito N, Okada T, Toba S, et al. New synthetic absorbable polymers as BMP carriers: plastic properties of poly-d,l-lactic acid-polyethylene glycol block copolymers. J Biomed Mater Res 1999; 47(1): 104-110.
18. Göpferich A and Tessmar J. Polyanhydride degradation and erosion. Adv Drug Deliver Rev 2002; 54(7): 911-931.
19. Huang X and Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 2001; 73(2-3): 121-136.
20. Tojo K, Aoyagi H and Kurita T. Surface dissolution-bulk erosion model of drug release from biodegradable polymer rods. J Chem Eng Jpn 1998; 31(4): 648-651.
21. Hedberg EL, Tang A, Crowther RS, et al. Controlled release of an osteogenic peptide from injectable biodegradable polymeric composites. J Control Release 2002; 84(3): 137-150.
22. Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliver Rev 2008; 60(8): 939-954.
23. Wang S. Ordered mesoporous materials for drug delivery. Micropor Mesopor Mat 2009; 117(1-2): 1-9.
24. Radin S, Chen T and Ducheyne P. The controlled release of drugs from emulsified, sol gel processed silica microspheres. Biomaterials 2009; 30(5): 850-858.
25. Slowing II, Vivero-Escoto JL, Wu CW, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliver Rev 2008; 60(11): 1278-1288.
26. Wu P and Grainger DW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006; 27(11): 2450-2467.
27. Barani H and Montazer M. A review on applications of liposomes in textile processing. J Liposome Res 2008; 18(3): 249-262.
28. Gabizon A and Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. P Natl Acad Sci USA 1988; 85(18): 6949-6953.
29. Li Y, Qi XR, Maitani Y, et al. PEG-PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations. Nanotechnology 2009; 20(5): 055106.
30. Matthews OA, Shipway AN and Stoddart JF. Dendrimers - branching out from curiosities into new technologies. Prog Polym Sci 1998; 23(1): 1-56.
31. Soliman GM, Sharma A, Maysinger D, et al. Dendrimers and miktoarm polymers based multivalent nanocarriers for efficient and targeted drug delivery. Chem Commun 2011; 47(34): 9572-9587.
32. McNerny DQ, Leroueil PR and Baker JR. Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2(3): 249-259.
33. Yamashita T, Yamashita K, Nabeshi H, et al. Carbon nanomaterials: efficacy and safety for nanomedicine. Materials 2012; 5(2): 350-363.
34. Vashist SK, Zheng D, Pastorin G, et al. Delivery of drugs and biomolecules using carbon nanotubes. Carbon 2011; 49(13): 4077-4097.
35. Liu Z, Robinson JT, Tabakman SM, et al. Carbon materials for drug delivery & cancer therapy. Mater Today 2011; 14(7-8): 316-323.
36. Zhang SA, Yang K and Liu ZA. Carbon nanotubes for in vivo cancer nanotechnology. Sci China Chem 2010; 53(11): 2217-2225.
37. Bianco A, Kostarelos K and Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005; 9(6): 674-679.
38. Le Guevel X, Daum N and Schneider M. Synthesis and characterization of human transferrin-stabilized gold nanoclusters. Nanotechnology 2011; 22(27): 275103.
39. Dobson J. Magnetic nanoparticles for drug delivery. Drug Develop Res 2006; 67(1): 55-60.
40. Losic D and Simovic S. Self-ordered nanopore and nanotube platforms for drug delivery applications. Expert Opin Drug Del 2009; 6(12): 1363-1381.
41. Trouiller B, Reliene R, Westbrook A, et al. Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice. Cancer Res 2009; 69(22): 8784-8789.
42. Hirakawa K, Mori M, Yoshida M, et al. Photo-irradiated titanium dioxide catalyzes site specific DNA damage via generation of hydrogen peroxide. Free Radical Res 2004; 38(5): 439-447.
43. Bergstrand N. Liposomes for drug delivery [Elektronisk resurs] from physico-chemical studies to applications. PhD Thesis, Acta Universitatis Upsaliensis, Uppsala, Sweden, 2003.
44. Chonn A and Cullis PR. Recent advances in liposomal drug-delivery systems. Curr Opin Biotech 1995; 6(6): 698-708.
45. Goyal P, Goyal K, Vijaya Kumar SG, et al. Liposomal drug delivery systems - clinical applications. Acta Pharmaceut 2005; 55(1): 1-25.
46. Rangaramanujam MK, Omathanu PP and Sujatha K. Biomedical applications of nanotechnology: dendrimers and hyperbranched polymers for drug delivery. In: V Labhasetwar V and Leslie-Pelecky DL (eds) Biomedical applications of nanotechnology. NJ: John Wiley & Sons, 2007, pp. 107-129.
47. Majoros IJ, Williams CR, Becker A, et al. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1(5): 502-510.
48. Lubbe AS, Bergemann C, Brock J, et al. Physiological aspects in magnetic drug-targeting. J Magn Magn Mater 1999; 194(1-3): 149-155.
49. Neuberger T, Schopf B, Hofmann H, et al. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005; 293(1): 483-496.
50. Han C-M, Lee E-J, Kim H-E, et al. Porous TiO2 films on Ti implants for controlled release of tetracycline-hydrochloride (TCH). Thin Solid Films 2011; 519(22): 8074-8076.
51. Yamaguchi S, Kobayashi H, Narita T, et al. Novel photodynamic therapy using water-dispersed TiO2-polyethylene glycol compound: evaluation of antitumor effect on glioma cells and spheroids in vitro. Photochem Photobiol 2010; 86(4): 964-971.
52. Zhang H, Wang C, Chen B, et al. Daunorubicin-TiO2 nanocomposites as a 'smart' pH-responsive drug delivery system. Int J Nanomed 2012; 7: 235-242.
53. Wang CY, Xiao XF, Mao D, et al. The study of using TiO2 nanotube arrays as a drug delivery for alendronate. In: Kim YH, Yarlagadda P, Zhang X, et al. et al. (eds) Advanced materials research, vols 335-336. Trans Tech Publications, 2011, pp. 1469-1472.
54. Song YY, Schmidt-Stein F, Bauer S, et al. Amphiphilic TiO2 nanotube arrays: an actively controllable drug delivery system. J Am Chem Soc 2009; 131(12): 4230-4232.
55. Cai R, Kubota Y, Shuin T, et al. Induction of cytotoxicity by photoexcited TiO2 particles. Cancer Res 1992; 52(8): 2346-2348.
56. Miyoshi N, Kyo K, Kotaro T, et al. Application of titanium dioxide (TiO2) nanoparticles in photodynamic therapy (PDT) of an experimental tumor. In: 4th nanoscience and nanotechnology symposium, vol. 1415 (eds F Iskandar, Khairurrijal, and M Abdullah), Bali, Indonesia, 23-25 September 2011, pp. 21-23. Melville, NY: American Institute of Physics.
57. Boffetta P, Soutar A, Cherrie JW, et al. Mortality among workers employed in the titanium dioxide production industry in Europe. Cancer Cause Control 2004; 15(7): 697-706.
58. Fryzek JP, Chadda B, Marano D, et al. A cohort mortality study among titanium dioxide manufacturing workers in the United States. J Occup Environ Med 2003; 45(4): 400-409.
59. Kresge CT, Leonowicz ME, Roth WJ, et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992; 359: 710-712.
60. Shchipunov YA, Burtseva YV, Karpenko TY, et al. Highly efficient immobilization of endo-1,3-beta-d-glucanases (laminarinases) from marine mollusks in novel hybrid polysaccharide-silica nanocomposites with regulated composition. J Mol Catal B: Enzym 2006; 40(1-2): 16-23.
61. Klichko Y, Liong M, Choi E, et al. Mesostructured silica for optical functionality, nanomachines, and drug delivery. J Am Ceram Soc 2009; 92(1): S2-S10.
62. Tourne-Peteilh C, Begu S, Lerner DA, et al. Sol-gel one-pot synthesis in soft conditions of mesoporous silica materials ready for drug delivery system. J Sol-Gel Sci Techn 2012; 61(3): 455-462.
63. Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008; 2(5): 889-896.
64. Trewyn BG, Slowing II, Giri S, et al. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Accounts Chem Res 2007; 40(9): 846-853.
65. Slowing II, Trewyn BG, Giri S, et al. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater 2007; 17(8): 1225-1236.
66. Vallet-Regi M, Balas F and Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Edit 2007; 46(40): 7548-7558.
67. Fan JQ, Fang G, Wang XD, et al. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Nanotechnology 2011; 22(45): 455102.
68. Vivero-Escoto JL, Slowing II, Trewyn BG, et al. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 2010; 6(18): 1952-1967.
69. Vallet-Regi M, Izquierdo-Barba I and Colilla M. Structure and functionalization of mesoporous bioceramics for bone tissue regeneration and local drug delivery. Philos T Roy Soc A 2012; 370(1963): 1400-1421.
70. Sakai-Kato K, Hasegawa T, Takaoka A, et al. Controlled structure and properties of silicate nanoparticle networks for incorporation of biosystem components. Nanotechnology 2011; 22(20): 205702.
71. Lee C-H, Cheng S-H, Huang I-P, et al. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed 2010; 49: 8214-8219.
72. Meng HA, Xue M, Xia TA, et al. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J Am Chem Soc 2010; 132: 12690-12697.
73. Shchipunov YA. Entrapment of biopolymers into sol-gel derived silica nanocomposites. In: Ruiz-Hitzky E, Ariga K and Lvov YM (eds) Bio-inorganic Hybrid Nanomaterials: strategies, syntheses, characterization and applications. Weinheim: Wiley-VCH Verlag GmbH & Co, KGaA, 2008, pp. 75-111.
74. Shchipunov YA, Kojima A and Imae T. Polysaccharides as a template for silicate generated by sol-gel processes. J Colloid Interf Sci 2005; 285(2): 574-580.
75. Wang YG, Huang SJ, Kang SF, et al. Low-cost route for synthesis of mesoporous silica materials with high silanol groups and their application for Cu(II) removal. Mater Chem Phys 2012; 132(2-3): 1053-1059.
76. Slowing II, Vivero-Escoto JL, Trewyn BG, et al. Mesoporous silica nanoparticles: structural design and applications. J Mater Chem 2010; 20: 7924-7937.
77. Wu S-H, Hung Y and Mou C-Y. Mesoporous silica nanoparticles as nanocarriers. Chem Commun 2011; 47: 9972-9985.
78. Fowler CE, Khushalani D, Lebeau B, et al. Nanoscale materials with mesostructured interiors. Adv Mater 2001; 13: 649-652.
79. Cai Q, Luo Z-S, Pang W-Q, et al. Dilute solution routes to various controllable morphologies of MCM-41 silica with a basic medium. Chem Mater 2001; 13: 258-263.
80. Lai C-Y, Trewyn BG, Jeftinija DM, et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc 2003; 125: 4451-4459.
81. Lu F, Wu S-H, Hung Y, et al. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 2009; 5: 1408-1413.
82. He Q, Cui X, Cui F, et al. Size-controlled synthesis of monodispersed mesoporous silica nano-spheres under a neutral condition. Micropor Mesopor Mat 2009; 117: 609-616.
83. Urata C, Aoyama Y, Tongawa A, et al. Dialysis process for the removal of surfactants to form colloidal mesoporous silica nanoparticles. Chem Commun 2009; 34: 5094-5096.
84. Suteewong T, Sai H, Cohen R, et al. Highly aminated mesoporous silica nanoparticles with cubic pore structure. J Am Chem Soc 2011; 133: 172-175.
85. Lin Y-S, Abadeer N and Haynes CL. Stability of small mesoporous silica nanoparticles in biological media. Chem Commun 2011; 47: 532-534.
86. Nooney RI, Thirunavukkarasu D, Chen Y, et al. Synthesis of nanoscale mesoporous silica spheres with controlled particle size. Chem Mater 2002; 14: 4721-4728.
87. Lin H-P and Tsai C-P. Synthesis of mesoporous silica nanoparticles from a low-concentration CnTMAX-sodium silicate components. Chem Lett 2003; 32: 1092-1093.
88. Suzuki K, Ikari K and Imai H. Synthesis of silica nanoparticles having a well-ordered mesostructure using a double surfactant system. J Am Chem Soc 2004; 126: 462-463.
89. Yano K and Fukushima Y. Synthesis of mono-dispersed mesoporous silica spheres with highly ordered hexagonal regularity using conventional alkyltrimethylammonium halide as a surfactant. J Mater Chem 2004; 14: 1579-1584.
90. Han Y and Ying JY. Generalized fluorocarbon-surfactant-mediated synthesis of nanoparticles with various mesoporous structure. Angew Chem Int Edit 2005; 44: 288-292.
91. Möller K, Kobler J and Bein T. Colloidal suspensions of nanometer-sized mesoporous silica. Adv Funct Mater 2007; 17: 605-612.
92. Berggren A and Palmqvist AEC. Particle control of colloidal suspensions of mesostructured silica. J Phys Chem C 2008; 112: 732-737.
93. Du HW, Hamilton PD, Reilly MA, et al. A facile synthesis of highly water-soluble, core-shell organo-silica nanoparticles with controllable size via sol-gel process. J Colloid Interf Sci 2009; 340(2): 202-208.
94. Chen Y, Chen HR, Ma M, et al. Double mesoporous silica shelled spherical/ellipsoidal nanostructures: synthesis and hydrophilic/hydrophobic anticancer drug delivery. J Mater Chem 2011; 21(14): 5290-5298.
95. Brook MA, Chen Y, Guo K, et al. Proteins entrapped in silica monoliths prepared from glyceroxysilanes. J Sol-Gel Sci Techn 2004; 31(1-3): 343-348.
96. Shchipunov YA, Karpenko TY and Krekoten AV. Hybrid organic-inorganic nanocomposites fabricated with a novel biocompatible precursor using sol-gel processing. Compos Interface 2005; 11(8-9): 587-607.
97. Colby MW, Osaka A and Mackenzie JD. Effects of temperature on formation of silica-gel. J Non-Cryst Solids 1986; 82(1-3): 37-41.
98. Shchipunov YA, Karpenko TY, Krekoten AV, et al. Gelling of otherwise nongelable polysaccharides. J Colloid Interf Sci 2005; 287(2): 373-378.
99. Halamova D and Zelenak V. NSAID naproxen in mesoporous matrix MCM-41: drug uptake and release properties. J Incl Phenom Macro 2012; 72(1-2): 15-23.
100. He QJ, Shi JL, Chen F, et al. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials 2010; 31(12): 3335-3346.
101. Mackenzie JD. Applications of the sol-gel process. J Non-Cryst Solids 1988; 100(1-3): 162-168.
102. Manzano M, Aina V, Arean CO, et al. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization. Chem Eng J 2008; 137(1): 30-37.
103. Doadrio JC, Sousa EMB, Izquierdo-Barba I, et al. Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern. J Mater Chem 2006; 16(5): 462-466.
104. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2(5): 347-360.
105. Vivero-Escoto JL and Luis J. Surface functionalized mesoporous silica nanoparticles for intracellular drug delivery. Diss Abstr Int 2009; 71: 0638.
106. Selvam P, Bhatia SK and Sonwane CG. Recent advances in processing and characterization of periodic mesoporous MCM-41 silicate molecular sieves. Ind Eng Chem Res 2001; 40(15): 3237-3261.
107. Wan Y and Zhao DY. On the controllable soft-templating approach to mesoporous silicates. Chem Rev 2007; 107: 2821-2860.
108. Hoffmann F, Cornelius M, Morell J, et al. Silica-based mesoporous organic - inorganic hybrid. Angew Chew Int Edit 2006; 45: 3216-3251.
109. Gary-Bobo M, Hocine O, Brevet D, et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int J Pharm 2012; 423(2): 509-515.
110. Yiu HHP and Wright PA. Enzymes supported on ordered mesoporous solids: a special case of an inorganic-organic hybrid. J Mater Chem 2005; 15(35-36): 3690-3700.
111. Huh S, Wiench JW, Trewyn BG, et al. Tuning of particle morphology and pore properties in mesoporous silicas with multiple organic functional groups. Chem Commun 2003; 18: 2364-2365.
112. Huh S, Wiench JW, Yoo JC, et al. Organic functionalization and morphology control of mesoporous silicas via a co-condensation synthesis method. Chem Mater 2003; 15: 4247-4256.
113. Lang N and Tuel A. A fast and efficient ion-exchange procedure to remove surfactant molecules from MCM-41 materials. Chem Mater 2004; 16: 1961-1966.
114. Burleigh MC, Markowitz MA, Spector MS, et al. Direct synthesis of periodic mesoporous organosilicas: functional incorporation by co-condensation with organosilanes. J Phys Chem B 2001; 105: 9935-9942.
115. Balas F, Manzano M, Horcajada P, et al. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 2006; 128(25): 8116-8117.
116. Colilla M, Izquierdo-Barba I and Vallet-Regi M. Phosphorus-containing SBA-15 materials as bisphosphonate carriers for osteoporosis treatment. Micropor Mesopor Mat 2010; 135(1-3): 51-59.
117. Vallet-Regi MA, Ruiz-Gonzalez L, Izquierdo-Barba I, et al. Revisiting silica based ordered mesoporous materials: medical applications. J Mater Chem 2006; 16(1): 26-31.
118. Wu CT and Chang J. Mesoporous bioactive glasses: structure characteristics, drug/growth factor delivery and bone regeneration application. Interface Focus 2012; 2(3): 292-306.
119. Vallet-Regi M, Doadrio JC, Doadrio AL, et al. Hexagonal ordered mesoporous material as a matrix for the controlled release of amoxicillin. Solid State Ionics 2004; 172(1-4): 435-439.
120. Kratz F, Muller IA, Ryppa C, et al. Prodrug strategies in anticancer chemotherapy. Chemmedchem 2008; 3(1): 20-53.
121. Li H, Zhang JZ, Tang Q, et al. Reduction-responsive drug delivery based on mesoporous silica nanoparticle core with crosslinked poly(acrylic acid) shell. Mater Sci Eng C Mater Biol Appl 2013; 33(6): 3426-3431.
122. Huang X, Hauptmann N, Appelhans D, et al. Source: synthesis of hetero-polymer functionalized nanocarriers by combining surface-initiated ATRP and RAFT polymerization. Small 2012; 8(23): 3579-3583.
123. Du L, Liao S, Khatib HA, et al. Controlled-access hollow mechanized silica nanocontainers. J Am Chem Soc 2009; 131: 15136-15142.
124. Ruhland TM, Reichstein PM, Majewski AP, et al. Superparamagnetic and fluorescent thermo-responsive core-shell-corona hybrid nanogels with a protective silica shell. J Colloid Interf Sci 2012; 374: 45-53.
125. Singh N, Karambelkar A, Gu L, et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J Am Chem Soc 2011; 133: 19582-19585.
126. Aznar E, Mondragón L, Ros-Lis JV, et al. Finely tuned temperature-controlled cargo release using paraffin-capped mesoporous silica nanoparticles. Angew Chem Int Edit 2011; 50: 11172-11175.
127. Chen C, Geng J, Pu F, et al. Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery. Angew Chem Int Edit 2011; 50: 882-886.
128. Ruiz-Hernández E, Baeza A and Vallet-Regi M. Smart drug delivery through DNA/magnetic nanoparticle gates. ACS Nano 2011; 5: 1259-1266.
129. Wu C, Chen C, Lai J, et al. Molecule-scale controlled-release system based on light-responsive silica nanoparticles. Chem Commun 2008; 23: 2662-2664.
130. Bernardos A, Mondragon L, Aznar E, et al. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with 'Saccharides'. ACS Nano 2010; 4: 6353-6368.
131. Luo Z, Cai K, Hu Y, et al. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. Angew Chem Int Edit 2011; 50: 640-643.
132. Feng J, Li J, Wu H, et al. Metabolic responses of HeLa cells to silica nanoparticles by NMR-based metabolomic analyses. Metabolomics 2013; 9: 874-886.
133. Fu C, Liu T, Li L, et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 2013; 34(10): 2565-2575.
134. Lee S, Kim M, Lee D, et al. The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice. Int J Nanomed 2013; 8: 147-158.